3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
28
Neoplasms
15
Carcinoma, Non-Small-Cell Lung
7
Multiple Myeloma
6
Hematologic Neoplasms
6
Neoplasm Metastasis
4
Lymphoma
4
Leukemia, Myeloid, Acute
3
Colorectal Neoplasms
3
Brain Neoplasms
3
Biliary Tract Neoplasms
3
Thyroid Neoplasms
2
Thyroid Cancer, Papillary
2
Skin Neoplasms
2
Glioma
2
Cholangiocarcinoma
2
Bile Duct Neoplasms
2
Adenocarcinoma, Follicular
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Oligodendroglioma
1
Nonseminomatous germ cell tumor
1
Neurofibromatosis 1
1
Neurofibroma, Plexiform
1
Neurocytoma
1
Neuroblastoma
1
Myelodysplastic Syndromes
1
Interventions
Sorafenib
52
pembrolizumab
26
Nivolumab
20
Bevacizumab
19
Radiosurgery
17
Doxorubicin
12
atezolizumab
9
Erlotinib Hydrochloride
9
lenvatinib
8
cabozantinib
7
Magnetic Resonance Spectroscopy
7
tremelimumab
6
durvalumab
6
Ramucirumab
6
Radiofrequency Ablation
6
Cisplatin
6
Sunitinib
5
tislelizumab
4
regorafenib
4
Oxaliplatin
4
Leucovorin
4
Ipilimumab
4
Fluorouracil
4
Everolimus
4
Capecitabine
4
nintedanib
3
fluoromisonidazole
3
carotuximab
3
bavituximab
3
Tomography, X-Ray Computed
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma, Hepatocellular
×
trametinib
×
Clear all
NCT02042443
2017-09-12
S1310
National Cancer Institute (NCI)
Phase 2
Completed
53 enrolled
13 charts